Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02170909
Recruitment Status : Completed
First Posted : June 23, 2014
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) rising doses in healthy male subjects of Japanese and Caucasian origin.

Condition or disease Intervention/treatment Phase
Healthy Drug: BIBR 1048 MS low dose Drug: BIBR 1048 MS medium dose Drug: BIBR 1048 MS high dose Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety, Pharmacokinetics and Pharmacodynamics After Single (150 mg, 220 mg and 300 mg) and Multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) Rising Oral Doses of BIBR 1048 MS/Capsules in Healthy Male Subjects of Japanese and Caucasian Origin. (Open Label Study)
Study Start Date : December 2004
Actual Primary Completion Date : June 2005

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIBR 1048 MS low dose Drug: BIBR 1048 MS low dose
Experimental: BIBR 1048 MS medium dose Drug: BIBR 1048 MS medium dose
Experimental: BIBR 1048 MS high dose Drug: BIBR 1048 MS high dose



Primary Outcome Measures :
  1. Change in vital signs [ Time Frame: Baseline and up to day 26 ]
  2. Change in 12-lead electrocardiogram (ECG) [ Time Frame: Baseline and up to day 26 ]
  3. Change in clinical laboratory tests [ Time Frame: Baseline and up to day 26 ]
  4. Occurence of adverse events [ Time Frame: Up to day 26 ]

Secondary Outcome Measures :
  1. Area under the curve (AUC) from 0-24 hours for activated partial thromboplastin time (aPTT) [ Time Frame: Day 1 and 12 ]
  2. AUC from 0-24 hours for ecarin clotting time (ECT) [ Time Frame: Day 1 and 12 ]
  3. Change in thrombin time (TT) [ Time Frame: Baseline and up to 72 hours after administration on day 1 and 12 ]
  4. Change in prothrombin time (PT) expressed as international normalised ratio (INR) [ Time Frame: Baseline and up to 72 hours after administration on day 1 and 12 ]
  5. Maximum value of aPTT [ Time Frame: Up to 72 hours after administration on day 1 and 12 ]
  6. Maximum value of ECT [ Time Frame: Up to 72 hours after administration on day 1 and 12 ]
  7. Change in ECT [ Time Frame: Baseline and up to 72 hours after administration on day 1 and 12 ]
  8. Change in aPTT [ Time Frame: Baseline and up to 72 hours after administration on day 1 and 12 ]
  9. Cmax (maximum measured concentration of the analyte in plasma) [ Time Frame: Up to 72 hours after administration on day 1 ]
  10. tmax (time from dosing to maximum measured concentration of the analyte in plasma) [ Time Frame: Up to 72 hours after administration on day 1 ]
  11. AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on day 1) [ Time Frame: Up to 72 hours after administration on day 1 ]
  12. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration) [ Time Frame: Up to 72 hours after administration on day 1 ]
  13. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: Up to 72 hours after administration on day 1 ]
  14. λz (terminal rate constant in plasma) [ Time Frame: Up to 72 hours after administration on day 1 ]
  15. t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: Up to 72 hours after administration on day 1 ]
  16. MRTpo (mean residence time of the analyte in the body after po administration) [ Time Frame: Up to 72 hours after administration on day 1 ]
  17. CL/F (apparent clearance of the analyte in plasma following extravascular administration) [ Time Frame: Up to 72 hours after administration on day 1 ]
  18. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration) [ Time Frame: Up to 72 hours after administration on day 1 ]
  19. Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2) [ Time Frame: Up to 72 hours after administration on day 1 ]
  20. fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2) [ Time Frame: Up to 72 hours after administration on day 1 ]
  21. CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) [ Time Frame: Up to 72 hours after administration on day 1 ]
  22. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  23. tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  24. Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  25. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  26. λz,ss (terminal rate constant in plasma at steady state) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  27. t1/2,ss (terminal half-life of the analyte in plasma at steady state) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  28. MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  29. CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  30. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  31. Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  32. fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  33. CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state) [ Time Frame: Up to 72 hours after the last dose on day 12 ]
  34. Accumulation ratio RA,Cmax,7 based on Cmax [ Time Frame: Day 6 to day 15 ]
  35. Accumulation ratio RA,AUC,7 based on AUCτ (only for 150 mg and 220 mg q.d. groups) [ Time Frame: Day 6 to day 15 ]
  36. Linearity index (LI) based on AUC (only for 150 mg and 220 mg q.d. groups) [ Time Frame: Day 6 to day 15 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male subjects of Japanese or Caucasian origin according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, respiratory rate and tympanic body temperature), 12- lead ECG (electrocardiogram), clinical laboratory tests

    • 1.1 No finding deviating from normal and of clinical relevance
    • 1.2 No evidence of a clinically relevant concomitant disease
  2. Age ≥ 20 and Age ≤ 45 years
  3. Body mass index (BMI) ≥ 18 and ≤ 25 kg/m2
  4. Japanese subjects were from a well-defined Japanese population, both parents of Japanese origin and the subjects have Japanese passport and had lived ≤ 8 years outside Japan.
  5. Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation.

Exclusion Criteria:

  1. Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women, or an unwillingness of male subjects to use an adequate form of contraception as well as having their female partner(s) use another form of contraception (if the woman possibly become pregnant) from the time of the single dose on Day 1 until Day 22-26 (end-of study examination)
  3. Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
  4. History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts
  5. Chronic or relevant acute infections
  6. History of

    • allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
    • any bleeding disorder including prolonged or habitual bleeding
    • other hematologic disease
    • cerebral bleeding (e.g. after a car accident)
    • concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
  7. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
  8. Use of acetylsalicylic acid (ASA)-containing over-the-counter medications, clopidogrel or ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs) (cyclooxygenase-2 (COX-2) inhibitors excluded), coumadin like anticoagulants, chronic use of corticosteroids, heparin and fibrinolytic agents within 14 days prior to administration or during the trial.
  9. Participation in another trial with an investigational drug within three months prior to administration or during the trial
  10. Smoker (> 10 cigarettes/day or > 3 cigars/day or > 3 pipes/day)
  11. Inability to refrain from smoking on trial days
  12. Alcohol abuse (more than 21unit/week; one unit was approximately half a pint of beer, a small glass of wine or one measure of spirits)
  13. History of drug abuse
  14. Blood donation (more than 100 mL within three months prior to screening administration and any blood donation from screening to end-of-study examination)
  15. Excessive physical activities (within one week prior to administration or during the trial and until end-of-study examination)
  16. Any laboratory value outside the reference range that was of clinical relevance
  17. Inability to comply with dietary regimen of study centre
  18. Known hypersensitivity to the drug or its excipients
  19. History of any familial bleeding disorder
  20. Thrombocytes < 150000/μL

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02170909     History of Changes
Other Study ID Numbers: 1160.29
First Posted: June 23, 2014    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Dabigatran
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants